RRD International
- Categories: Biotechnology, Life Sciences, Pharmaceutical
- Client: RRD International
Website: http://www.rrdintl.com/
The Chase Group proudly announces the successful completion of a search for the Chief Development Officer/Chief Medical Officer position for RRD International. Dr. Ulrich Thienel will assume this leadership role within the company. Dr. Thienel will oversee the product development team as well as work with the President, CEO, and other members of the senior management team to create a business strategy that will maximize the ability of RRD to partner with pharmaceutical and biotechnology companies and investor groups.
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on…
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in…-
Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate… 
The Chase Group Places VP of Clinical Development and Pharmacovigilance at Marinus Pharmaceuticals
The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical…-
The Chase Group Secures the Vice President, US and Global Medical Affairs for Eli Lilly
The Chase Group is pleased to announce the successful completion of the Vice President, US and Global Medical Affairs at Eli Lilly. The new Vice… 
Ionis Pharmaceuticals Secures Associate Director, Investor Relations
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor…